40.Issue 06 june 23 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 10, Issue : 06, June – 2023

Title:

40.PHARMACODYNAMIC STUDIES ON DRUG-DRUG INTERACTION BETWEEN VALSARTAN AND METFORMIN

Authors :

Kommuri Revathi, Kondala Roja Ramani, Kornana Pavan Kumar,Kotamahanthi Sujatha, Kuppa Sridevi, Lotti Chandrika, Chandaka Madhu

Abstract :

A drug interaction can be defined as the modification of the effects of one drug by the prior and concomitant administration of other drug. Polypharmacy and multiple drug therapy assume importance in present day clinical practice, since newer molecules are invented everyday and newer challenges face clinicians in managing either a single disease or simultaneously occurring different diseases. The present study was under taken to verify the possible drug-drug interaction if any between valsartan on hypoglycemic activity of metformin in normal and diabetic rats. The whole study is divided into four phases, clearly explained in following study. From the results obtained and concluded that Valsartan has shown hypoglycemia when administered alone in both normal and diabetic rats. Valsartan (5mg/kg) has altered peak hypoglycemia but not significantly alter onset and the duration of hypoglycemia induced by metformin in both healthy and diabetic albino rats but valsartan (10 mg/kg, 20mg/kg, 40 mg/kg) has no significant alteration in onset and the duration of hypoglycemia but altered the peak plasma levels in dose dependent manner with maximum decrease of 60% with higher dose. The maximum percentage decrease in peak plasma levels of metformin was 50%.
Key words: polypharmacy, valsartan, metformin, hypoglycemic activity.

Cite This Article:

Please cite this article in press Chandaka madhu et al, Pharmacodynamic Studies On Drug-Drug Interaction Between Valsartan And Metformin., Indo Am. J. P. Sci, 2023; 10 (06).

Number of Downloads : 10

References:

1. AJ Scheen; Renin-angiotensin system inhibition prevents type 2 diabetes mellitus; J Diabetes & Metab, 30, 2004, 498-505.
2. American diabetes association; Gestational diabetes mellitus; Diabetes care, 26(1), 2003, 103-105.
3. Ankur Rohilla, Shahjad Ali; Alloxan Induced Diabetes: Mechanisms and Effects; International journal of Research in pharmaceutical and biomedical sciences, 3, 2012, 819-823.
4. B. Ellen byrne; Drug interactions: a review and update; Endodontic Topics, 4, 2003, 9-21.
5. Bailey CJ; Biguanides and NIDDM; Diabetes Care, 15, 1992, 755-72.
6. Barry Stults, Robert E, Jones; Management of Hypertension in Diabetes; Diabetes Spectrum, 19(1), 2006, 25-31.
7. B.B.P guptha; Mechanism of Insulin Action; Current Science, 73(11), 1997,993.
8. Biswas PN., Wilton LV, Shakir SW; The safety of valsartan: results of a post marketing surveillance study on 12881 patients in England; J Hum Hyper, 16, 2002, 795-803.
9. Bokhari S, Israelian Z, Schmidt J, Brinton E, Meyer C; Effects of Angiotensin II Type 1 10.Receptor Blockade on β-Cell Function in Humans; Diabetes Care, 30( 1), 2007 , 181.
10. Brahmankar D.M, Sunil B. Jaiswal; Biopharmaceutics and pharmacokinetics a treatise. Pharmacokinetic drug interactions. 2nd ed., vallabh prakashan; 2009, 226-233.
11. Canadian Family Physician;Valsartan Just a second- line antihypertensive drug; Canadian Family Physician, 45, 1999, 2626-2628.
12. Charles M. Clark Jr., MD. Oral Therapy in Type 2 Diabetes; Pharmacological Properties and Clinical Use of Currently Available Agents; Diabetes Spectrum, 11 (4), 1998, 211-221.
13. Cheng JT, Huang CC, Liu IM, Tzeng TF, Chang CJ; Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats; Diabetes, 55(3), 2006, 819-25.
14. Cheng JT, Huang CC, Liu IM, Tzeng TF, Chang CJ; Metformin improves cardiac function in rats via activation of AMP-activated protein kinase; Clinical and Experimental Pharmacology and Physiology, 38(2), 2011, 94-101.
15. Choi YH, Lee MG; Pharmacokinetic and pharmacodynamic interaction between nifedipine and metformin in rats: competitive inhibition for metabolism of nifedipine and metformin by each other via CYP isozymes; Xenobiotica, 42(5), 2012, 483-95.
16. Clermont A, Bursell SE, Feener EP; Role of the angiotensin II type 1 receptor in the pathogenesis of diabetic retinopathy: effects of blood pressure control and beyond; J Hypertension Suppl, 24(1), 2006, 73-80.
17. Croom, Katherine F; Keating, Gillian M; Valsartan: A Review of its Use in Patients with Heart Failure and/or Left Ventricular Systolic Dysfunction After Myocardial Infarction; Am J Cardiovasc Drugs , 2004, 4 (6), 395-404
18. Curtis Triplitt. Drug; Interactions of Medications Commonly Used in Diabetes; Diabetes Spectrum, 19(4), 2006, 202-211.
19. Dandona P, Kumar V, Aljada A, Ghanim H, Syed T, Hofmayer D, Mohanty P, Tripathy D, Garg R; Angiotensin II Receptor Blocker Valsartan Suppresses Reactive Oxygen Species Generation in Leukocytes, Nuclear Factor-B, in Mononuclear Cells of Normal Subjects: Evidence of an Anti-inflammatory Action; J Clin Endocrinol Metab, 88(9), 2003, 4496–4501.
20. David J Woods, Formulation in Pharmacy Practice 2nd Edition. PharmInfoTech ,2001,390.
21. Disease of the Kidneys Evolved Into a Kidney Disease; Advances in Chronic Kidney Disease; 12(2), 2005, 223-229.
22. 22.E. K. Schmidt, K.-H. Antonin, G. Flesch, A. Racine-Poon; An interaction study with cimetidine and the new angiotensin II antagonist valsartan; European Journal of Clinical Pharmacology, 53(6), 1998, 451-458.
23. Ferdinand KC, Taylor C; the Management of Hypertension with Angiotensin Receptor Blockers in Special Populations; Clin Cornerstone, 9(3), 2009, 5-17.
24. Flesch G., Muller Ph., Lloyd P; Absolute bioavailability and pharmacokinetics of valsartan, an angiotenin II receptor antagonist in man; Eur J Clin Pharmcol, 52, 1997, 115-120.
25. Garabed Eknoyan, Judit Nagy; A History of Diabetes Mellitus or How a disease of the kidneys evolved into a kidney disease; Advances in Chronic Kidney Disease, 12(2), 2005, 223-229.

</div8